Boulder, Montana, kept my dad alive. So did the government. My father never quite understood how I could live in New York City. He preferred Montana, open rather than dense, prairie rather than ...

The FDA approved the poly ADP ribose polymerase (PARP) inhibitor in June 2023 in combination with enzalutamide for men with ...

The results of this phase III KEYNOTE-991 study do not support the addition of pembrolizumab to enzalutamide and ADT for the treatment of mHSPC,” researchers wrote.

As of this writing, the role of PD-L1 inhibitors in prostate cancer remains limited to a subset of patients with metastatic microsatellite instability-high, mismatch repair-deficient, or tumor ...

Duke University has been studying a new treatment for prostate cancer patients. Doctors say it is helping them live longer.

A new treatment approach is giving men with advanced prostate cancer more years to live.